Aarkstore.com announce a new report through its very spacious collection of market research report :
Case Study: Sepsis - Xigris' disappointing completion creates a market opportunity for improved sepsis therapies
For some-more information, Great fully visit:
http://www.aarkstore.com/reports/Case-Study-Sepsis-Xigris'-disappointing-consummation-creates-a-market-opportunity-for-improved-sepsis-therapies-136229.html
Introduction
Sepsis has southerly mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign (SSC) has helped to augment global awareness, standardize patient care, and lessen levels of mortality for sepsis. Negative clinical vexation data have dented the commercial playing of Eli Lilly's Xigris, creating ~y opportunity for improved sepsis therapeutics.
Features and benefits
* Profile and clinical and arising from traffic evaluation of Eli Lilly's Xigris (drotrecogin alfa [activated]).
* Review of unmet necessarily for sepsis and future challenges and opportunities in sepsis diagnosis and treatment.
* Overview of the Surviving Sepsis Campaign, including some evaluation of its impact on sepsis lenient care.
Highlights
Eli Lilly's Xigris is currently the only marketed direct therapy in the place of sepsis. However, its commercial performance has been disappointing, malignity its market monopoly, due to negative results from clinical trials conducted despatch-approval. Upcoming results from the PROWESS-SHOCK chagrin are likely to be critical to the coming time success of the drug.
There is a obscure unmet need for the identification and utilization of sepsis biomarkers that can identify those patients who would greatest in quantity likely benefit from new drugs and overseer patient response to therapies. However, current approaches dearth the required predictive capability and reliability to be employed in clinical habitual doing.
The Surviving Sepsis Campaign (SSC) has proved happy in increasing global awareness of sepsis, standardizing resigned care, and reducing patient mortality rates. However, the progress to maturity of the SSC guidelines has been associated with controversy due to links with efforts (particularly Eli Lilly).
Your key questions answered
* Understand the trading and clinical attractiveness of Eli Lilly's Xigris and the explanation reasons behind its disappointing commercial playing.
* Understand key unmet needs in sepsis and in posse future developments in diagnosis and therapy.
* Gain deep view into the Surviving Sepsis Campaign and its drive firmly together on sepsis management.
Table of Contents :
Executive Summary
Strategic scoping and point of convergence
key findings
Related reports
OVERVIEW
Catalyst
Summary
TREATMENT GUIDELINES
The SSC guidelines end to translate evidence-based patient contrivance recommendations into clinical practice
The Surviving Sepsis Campaign
Upon introduction, the key aim of the SSC was to drive a significant reduction in mortality from satirical sepsis and septic shock
The SSC has had a positive impact on standardizing and guiding sepsis unrepining care and reducing levels of necessity of dying
Sources of funding, incorporation of Xigris in the SSC guidelines, and committee members' links to Eli Lilly are among questions raised over the influence of busy vigor on the SSC
PRODUCT PROFILE: XIGRIS
Drug profile
Historic sales overview
A restricted label and inauspicious clinical trial data have harmed the receipts potential of Xigris
Development overview
Clinical wretchedness results for Xigris released since its throw have proved harmful to its engaged in traffic performance
SWOT analysis
A range of clinical weaknesses last ~ and testament continue to harm the commercial prospects on this account that Xigris, despite large markets and signifying opportunities for the drug
Product positioning
Reduction in necessity of dying in critically ill patients is the key brand message for Xigris
Physician recognition of Xigris
Despite its well-publicised drawbacks, physicians avow that Xigris is an efficacious mix with ~s in the patient group for what one. it is indicated
Clinical and relating to traffic attractiveness
A restricted label and preservation issues limit the market opportunity as being sepsis, despite a large potential invalid population
The strong sales and marketing capabilities of Eli Lilly and a unmistakable brand message have been unable to significantly elevate sales of Xigris
UNMET NEEDS
With upright one marketed therapy, there is a powerful unmet need for new efficacious and secure sepsis drugs and therapeutic approaches
Improvements in clinical experiment design would facilitate a more just evaluation of new sepsis drugs
Biomarkers may frisk a crucial future role in sepsis diagnosis and management, although substantial challenges remain before they be possible to be integrated into clinical practice
BIBLIOGRAPHY
Journal papers
Websites
APPENDIX A
Data definitions, limitations, and assumptions
Exchange rates
APPENDIX B
Contributing experts
Conferences attended
Report methodology
